Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

750 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A multicentre randomised phase II trial of gemcitabine alone vs gemcitabine and S-1 combination therapy in advanced pancreatic cancer: GEMSAP study.
Nakai Y, Isayama H, Sasaki T, Sasahira N, Tsujino T, Toda N, Kogure H, Matsubara S, Ito Y, Togawa O, Arizumi T, Hirano K, Tada M, Omata M, Koike K. Nakai Y, et al. Among authors: toda n. Br J Cancer. 2012 Jun 5;106(12):1934-9. doi: 10.1038/bjc.2012.183. Epub 2012 May 3. Br J Cancer. 2012. PMID: 22555398 Free PMC article. Clinical Trial.
Multicenter, phase II study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer.
Sasaki T, Isayama H, Nakai Y, Ito Y, Kogure H, Togawa O, Toda N, Yasuda I, Hasebe O, Maetani I, Sasahira N, Hirano K, Tsujino T, Tada M, Omata M. Sasaki T, et al. Among authors: toda n. Cancer Chemother Pharmacol. 2010 May;65(6):1101-7. doi: 10.1007/s00280-009-1115-5. Epub 2009 Aug 26. Cancer Chemother Pharmacol. 2010. PMID: 19707761 Clinical Trial.
Impact of S-1 on the survival of patients with advanced pancreatic cancer.
Nakai Y, Isayama H, Sasaki T, Sasahira N, Ito Y, Kogure H, Togawa O, Matsubara S, Arizumi T, Yagioka H, Yashima Y, Kawakubo K, Mizuno S, Yamamoto K, Hirano K, Tsujino T, Ijichi H, Tateishi K, Toda N, Tada M, Omata M, Koike K. Nakai Y, et al. Among authors: toda n. Pancreas. 2010 Oct;39(7):989-93. doi: 10.1097/MPA.0b013e3181d91936. Pancreas. 2010. PMID: 20467352
Prognostic factors in patients with advanced biliary tract cancer receiving chemotherapy.
Sasaki T, Isayama H, Nakai Y, Togawa O, Kogure H, Ito Y, Yamamoto K, Mizuno S, Yagioka H, Yashima Y, Kawakubo K, Arizumi T, Matsubara S, Sasahira N, Hirano K, Tsujino T, Toda N, Tada M, Omata M, Koike K. Sasaki T, et al. Among authors: toda n. Cancer Chemother Pharmacol. 2011 Apr;67(4):847-53. doi: 10.1007/s00280-010-1360-7. Epub 2010 Jun 20. Cancer Chemother Pharmacol. 2011. PMID: 20563811
Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine.
Sasaki T, Isayama H, Nakai Y, Mizuno S, Yamamoto K, Yagioka H, Yashima Y, Kawakubo K, Kogure H, Togawa O, Matsubara S, Ito Y, Sasahira N, Hirano K, Tsujino T, Toda N, Tada M, Omata M, Koike K. Sasaki T, et al. Among authors: toda n. Invest New Drugs. 2012 Apr;30(2):708-13. doi: 10.1007/s10637-010-9553-9. Epub 2010 Oct 6. Invest New Drugs. 2012. PMID: 20924641 Clinical Trial.
Improvement of prognosis for unresectable biliary tract cancer.
Sasaki T, Isayama H, Nakai Y, Takahara N, Sasahira N, Kogure H, Mizuno S, Yagioka H, Ito Y, Yamamoto N, Hirano K, Toda N, Tada M, Omata M, Koike K. Sasaki T, et al. Among authors: toda n. World J Gastroenterol. 2013 Jan 7;19(1):72-7. doi: 10.3748/wjg.v19.i1.72. World J Gastroenterol. 2013. PMID: 23326165 Free PMC article.
A randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine monotherapy for advanced biliary tract cancer.
Sasaki T, Isayama H, Nakai Y, Ito Y, Yasuda I, Toda N, Kogure H, Hanada K, Maguchi H, Sasahira N, Kamada H, Mukai T, Okabe Y, Hasebe O, Maetani I, Koike K. Sasaki T, et al. Among authors: toda n. Cancer Chemother Pharmacol. 2013 Apr;71(4):973-9. doi: 10.1007/s00280-013-2090-4. Epub 2013 Jan 26. Cancer Chemother Pharmacol. 2013. PMID: 23355041 Clinical Trial.
Treatment outcomes of chemotherapy between unresectable and recurrent biliary tract cancer.
Sasaki T, Isayama H, Nakai Y, Ito Y, Yasuda I, Toda N, Yagioka H, Matsubara S, Hanada K, Maguchi H, Kamada H, Hasebe O, Mukai T, Okabe Y, Maetani I, Koike K. Sasaki T, et al. Among authors: toda n. World J Gastroenterol. 2014 Dec 28;20(48):18452-7. doi: 10.3748/wjg.v20.i48.18452. World J Gastroenterol. 2014. PMID: 25561816 Free PMC article. Clinical Trial.
750 results